Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Outperform rating, reflecting strong confidence in the drug's potential. The company plans to resubmit its FDA application by the end of 2026, with a decision expected by mid-2027. This progress highlights a promising future for treating this rare light-sensitive condition.
Disc Medicine's recent trial results provide context for health sector activity on Pluang. As of Oct 19, 2026 22:21 WIB, 73 of 150 priced Health-sector US stocks rose while 70 fell. Notable movers include Moderna at USD 225.85 with a 3.60% gain and Butterfly Network Inc. at USD 7.51 with a 3.59% gain.
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
Marvell Technology executive Bharathi Sandeep sold 3,685 shares worth about $865,864 amid market pressure on AI chip stocks following warnings from Broadcom's CEO about AI funding. Despite strong AI-related results, Marvell's stock faces valuation co...
